International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The main goal of this study is to improve the outcome of children and adolescents with
standard risk (SR) first relapsed acute lymphoblastic leukemia. Furthermore, goal is to set
up a large international study group platform allowing for optimization of standard treatment
strategies and integration of new agents.
Phase:
Phase 3
Details
Lead Sponsor:
Charite University, Berlin, Germany University Hospital of Berlin
Collaborators:
Australian & New Zealand Children's Haematology/Oncology Group Central Manchester University (Co-Sponsor United Kingdom) Centre Hospitalier Universitaire de Nice Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen) European Organisation for Research and Treatment of Cancer - EORTC Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa) Medical University of Wroclaw (Co-Sponsor Poland) National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan) Oslo University Hospital (Co-Sponsor Oslo) Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy) Our Lady's Chilrden's Hospital (Co-Sponsor Ireland) Prinses Máxima Centrum (Co-Sponsor Netherlands) Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain) St. Anna Kinderkrebsforschung (Co-Sponsor Austria) Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel) Turku University (Co-Sponsor Finland) University Children's Hospital, Zurich University Hospital Motol (Co-Sponsor Czech Republic) University Hospital Stockholm (Co-Sponsor Sweden)